SLNO (Soleno) Net Assets per Single Share

Symbol and logo of brand Soleno Therapeutics (SLNO)

This daily price chart for Soleno Therapeutics (SLNO) shows quotes at 9.65. Current growth is hampered by geopolitical tensions, which complicate component imports and limit the scale of medical trials. The business relies on the development of DCCR, a unique treatment for Prader-Willi syndrome with exclusive status. All resources are currently focused on bringing this breakthrough metabolic product to market.

SLNO Soleno Therapeutics Inc Share Book Value (07/04/2022 - 05/30/2026)

Summary analytical data breakdowns for soleno.life (SLNO)

- current quotes and average value forecast:
Price Chart Soleno|SLNO - Broker Consensus Forecast
- business market valuation indicators:
Market Value Soleno Therapeutics, Inc.|SLNO - Total Enterprise Value
- shareholders' equity book value data:
Net Assets per Single Share Soleno Therapeutics|SLNO - Net Asset Value|Market Capitalization to Book Value Ratio soleno.life|SLNO - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital Soleno Therapeutics|SLNO - Long-Term Debt to Capital|Short-Term Debt to Equity Soleno Therapeutics, Inc.|SLNO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Soleno Therapeutics, Inc.|SLNO - Company Long-Term Liabilities|Company Short-Term Debts Soleno Therapeutics
General company analysis:SLNO - Soleno
Manufactured products of Soleno Therapeutics, Inc.

Book value per share is calculated as the difference between total assets and liabilities, divided by the number of outstanding shares. This metric determines the intrinsic value of an investor's stake, reflecting the actual capitalization of net assets. For Soleno Therapeutics (SLNO), this calculation is critical due to the development costs of the Prader-Willi syndrome therapy. The bps trend demonstrates capital resilience during the clinical trial period. Analysis of the bps metric allows for an assessment of the risk of frozen funds during a change in the market cycle.

Competitor analysis

ASND - Net Assets per Single Share|MDGL (Madrigal Corp) - Equity per Share|Corcept Therapeutics (CORT) - Net Assets per Single Share|Net Asset Value per Share rhythmtx.com (RYTM)|Net Assets per Single Share Akero|Metsera, Inc. - Share Book Value|Book Value per Share MLTX|CRNX (Crinetics Corp) - Accounting Value of a Share|Book Value per Share NAMS (NewAmsterdam Pharma)|Book Value per Share amicusrx.com FOLD|ETNB - Net Assets per Single Share|Accounting Value of a Share AGIO (Agios)|Structure Pharma (GPCR) - Net Assets per Single Share|Accounting Value per Share MiMedx Corp|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com|Accounting Value per Share MBX (MBX Biosciences)|ALT (Altimmune Inc) - Accounting Value of a Share|Net Assets per Single Share Aardvark Therapeutics Corp AARD|SGMT - Accounting Value per Share|BioAge Labs, Inc. - Book Value per Share|Net Asset Value per Share biomeafusion.com|QNCX (quincetx.com) - Accounting Value per Share|GUTS: Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share PLUR|Net Assets per Single Share SYBX (synlogictx.com)|Net Assets per Single Share Lipocine LPCN|Matinas BioPharma Holdings, Inc. (MTNB) - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO: Net Assets per Single Share|CTCX: Book Value per Share|LUMO - Net Assets per Share|Net Assets per Single Share Organovo|Radius Recycling Inc. (RDUS) - Net Assets per Share